View Archive

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Agios Pharmaceuticals, Inc., and Incyte Corporation.

ASCO GI: A New Wave of Progress in Cholangiocarcinoma: Optimizing Outcomes from Diagnosis to Treatment

ASCO GI: A New Wave of Progress in Cholangiocarcinoma: Optimizing Outcomes from Diagnosis to Treatment

Thursday, January 23, 2020

Dinner and Registration: 6:00 pm – 7:00 pm
Scientific Session: 7:00 pm – 9:00 pm

San Francisco Marriott Marquis
Dinner and Program: Yerba Buena Ballroom, Salon 7
780 Mission St, San Francisco, CA 94103
Phone: (415) 896-1600


Advances in cholangiocarcinoma, also known as biliary tract cancer, have been lacking in comparison to the significant paradigm shifts in treatment for other advanced cancers, such as lung cancer or even hepatocellular carcinoma. Cholangiocarcinoma is a rare malignancy, and a remarkably aggressive disease, with most patients having advanced-stage disease at the time of diagnosis. While surgical and locoregional therapies for early -stage disease can yield significantly survival improvements, patients with unresectable advanced cholangiocarcinoma have a poor prognosis, with 5-year overall survival rates between 5% and 10%. Current treatment options available for these patients are of limited benefit; most patients receive palliative care, which may include the use of systemic chemotherapy with sorafenib or gemcitabine plus cisplatin, biliary stenting, or locoregional treatments. Thus, there is a pressing need to discover novel targets and effective treatments for this malignancy based on molecular and genomic advances. Already promising preliminary data in cholangiocarcinoma treatment suggest a strong rationale for agents targeting isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2), fibroblast growth factor receptor (FGFR), immune checkpoint proteins, tumors that are microsatellite instability-high (MSI-H), and other multi-targeted tyrosine kinase inhibitors (TKIs).

This ancillary satellite symposium will be held adjunct to the 2020 Gastrointestinal Cancers Symposium (ASCO GI) on January 23, 2020, in San Francisco, CA. The CME-accredited live educational program is designed to aid physicians in assessing the latest available data on immunotherapeutic and molecularly targeted treatment strategies for the care of patients with cholangiocarcinoma. This program will cover a didactic epidemiological overview of cholangiocarcinoma, major prognostic factors and indicators, significance of early detection and intervention, latest diagnostic advancements, improvements in genomics and the role of next-generation sequencing, and the development of novel targets currently being investigated in clinical trials. A case-based panel discussion will present typical and atypical patient profile case scenarios, following the patient from diagnosis through treatment, to help clinicians improve outcomes for their patients with cholangiocarcinoma. In the rapidly changing landscape of oncology, oncologists and other healthcare professionals on the multidisciplinary team need to be aware of emerging diagnostic recommendations, current advances in the management of cholangiocarcinoma, and highly anticipated results in the field that may soon alter treatment paradigms and standards of care. In this exciting time for the evolution of cholangiocarcinoma care, we look forward to your participation in this live, informative meeting.

Benefits of Participation

  • Network with other experts interested in the treatment of cholangiocarcinoma
  • Learn about novel targets for the treatment of cholangiocarcinoma guided by advancements in understanding biomarkers and pathophysiology
  • Obtain expert recommendations for best practices in managing and treating patients with cholangiocarcinoma
  • Gain insights into how the experts handle challenging, real-world clinical cases in cholangiocarcinoma

Acknowledgement of Commercial Support

This activity is supported by educational grants from Agios Pharmaceuticals, Inc., and Incyte Corporation.

Target Audience: HCPs Who Treat Pancreatic Cancer

This educational program is directed toward all attendees of the 2020 Gastrointestinal Cancers Symposium, including medical oncologists, surgical oncologists, radiation oncologists, hepatologists, pathologists, and gastroenterologists interested in the treatment of cholangiocarcinoma. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with cholangiocarcinoma will be invited to participate.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss advancements in genomics and molecular markers and their influence on cholangiocarcinoma management
  • Apply the latest strategies to promptly and accurately diagnose cholangiocarcinoma based on tumor location and biomarkers
  • Evaluate current standard- of- care approaches in the clinical management of cholangiocarcinoma
  • Synthesize emerging data from recent clinical trials of novel therapies for cholangiocarcinoma

Program Chair

Ghassan K. Abou-Alfa
Ghassan K. Abou-Alfa, MD, MBA
Professor of Medicine
Weill Medical College of Cornell University
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY


2 Ways to Register
  1. Online: Click here.
  2. Phone: Please call +1-(888)-949-0045 or +1-(609)-378-3701.
Physicians' Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Calendar of Events
Filter By